Skip to Main Content

Paper Details

Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Ophthalmology
37
2015
Author NameAffiliation
Usha ChakravarthyRoyal Victoria Hospital
Louise DowneyHull and East Yorkshire Eye Hospital
Richard GaleYork Teaching Hospital
Sobha SivaprasadKings College Hospital
  • 1 - 4

Datasets

Release 1.2